SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " regeneron " 53 found 🔀 AI-powered Shuffle
Sign in to save shuffle history.
Jericho High School student Ashka Shah named Regeneron Science Talent Search finalist
The Nassau County student was one of 40 winners announced Wednesday.
Jericho High contestant says everyone's a winner at Regeneron science finals
Jericho High School senior Ashka Shah was among the finalists at the Regeneron Science Talent Search in Washington D.C.
Meet Iris Shen, the 17-year-old Texas student who used clams as a model for testing blood-cancer drugs, found a drug combination that slowed tumor growth, and won a $150,000 Regeneron Science Talent Search prize
Iris Shen, a 17-year-old student from The Woodlands, Texas, has earned third place and a $150,000 award in the 2026 Regeneron Science Talent Search for an unusually creative approach to blood-cancer research. Instead of relying only on conventional laboratory models, Shen tested a potential cancer drug in clams to determine whether these animals could serve as an animal model for blood-cancer drug discovery.
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
With a detailed data drop that AstraZeneca’s R&D chief described as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become a flagship biologic in chronic obstructive pulmonary disease (COPD). In detailed results from the late-stage Oberon and Titania trials—first teased in March and detailed in full at the European Respiratory Society Congress in Barcelona this week—the drugmaker laid out the extent of its IL-33 inhibitor’s potential to reduce moderate and severe exacerbations in a wide range of COPD patients still struggling with those “lung attacks,” as AstraZeneca’s Sharon Barr, Ph.D., called them, despite using standard-care inhaled therapy. In the headline results, a 300 mg dose of tozorakimab given once every four weeks curbed those moderate and severe exacerbations in the studies’ primary population of former smokers by 29% in the Oberon study and 34% in Titania. In the overall population of both current and former smokers, these reductions were 30% and 29%, respectively, versus placebo and inhaled standard of care. The benefits also extended to clinically meaningful exacerbation reductions in all prespecified patient subgroups and specifically turned up promising signals in patients across a range of blood eosinophil counts, with Barr telling Fierce that “it’s the details that make this even more exciting than the high-level results that we’ve already shared.” In fact, during AZ’s tozorakimab poster presentation at the ERS 2026 Congress this past weekend, attendees were so enamored by the data that event organizers had to encourage people to clear the room and look at the other presentations on offer, Barr said in an interview. “I think it really speaks to the fact that there is a lot of buzz around these data because the entire respiratory community has been so desperate for new therapies for these patients,” she explained. The respiratory disease continues to represent a “staggering unmet medical need,” Barr said, highlighting the COPD exacerbations that the Oberon and Titania studies homed in on, which she added carry a greater mortality risk than a heart attack. “When a patient has a severe exacerbation, only about half of them are still alive within three and a half years,” she pointed out. As for tozorakimab specifically, Barr christened the molecule “an AstraZeneca science success story,” harkening several years back to the point at which researchers began to explore IL-33 as a driver of respiratory disease, and COPD in particular. At the same time, “there was still so much that wasn’t understood,” she admitted, highlighting the insight that IL-33 signals through both ST2 and EGFR through the RAGE pathway, a discovery Barr attributed to AstraZeneca's own scientists. Understanding the need to tackle both pathways in COPD—and aware of competitor candidates in the hopper, including one that bound ST2—the company ultimately had to make some “courageous decisions,” Barr said. These included taking a prior COPD molecule offline and going back to the drawing board to reinvent its potential IL-33 label “to make sure that we had a molecule that could block signaling through both arms of the pathway, through both the reduced form and the oxidized form, knowing that we wouldn’t be first, but striving to be best.” “When we put [tozorakimab] into the clinic, we firmly believed that we had a differentiated molecule, and we saw the other molecules blocking just ST2 or partially blocking IL-33, unable to deliver two positive pivotal studies in COPD,” Barr explained. “We kept marching forward because we believed our molecule was differentiated, and now I think we have the clinical validation that supports that.” Ultimately, AstraZeneca finds itself on much better footing these days when it comes to potential biologic rivals to tozorakimab in COPD. Sanofi and Regeneron’s Dupixent, for instance, is approved to treat COPD exacerbations in patients with high eosinophil counts, but not low ones. Meanwhile, the future has become cloudier for other next-gen IL-33 candidates from Sanofi and Regeneron, as well as Roche, which have suffered trial flops in recent years. One other potential ingredient for AstraZeneca’s success in its duo of studies was that the company was “ambitious in the trial design, willing to look at an all-comers population,” Barr said, “and willing to enroll the most severe patients.” Prior studies for would-be biologics rivals in COPD “avoided enrolling” those patients, she pointed out. She also highlighted the Big Pharma’s painstaking design of exacerbations in its trial, which “gave us a very rigorous readout,” and pointed to “the extra effort and investment” the company put in to understand the effect of mucus plugs in patients. Barr described mucus production as a “key feature in disease diversity,” noting that mucus plugs—obstructing clumps of mucus that block patients’ airways—are associated with worse outcomes in COPD. In its data announcement, AstraZeneca noted that an integrated analysis of Oberon and Titania found tozorakimab “demonstrated a reduction in patients’ mucus plug score,” with the pharma claiming its biologic is the first to deliver such results in a broad COPD population. “So being able to reduce those mucus plugs, we expect, is an important part of driving benefit for patients who are living with COPD,” Barr said. Again touching on the breadth of the study populations, Barr added that tozorakimab “worked across all eosinophil levels in both current and former smokers across all levels of lung function,” which she suggested “really simplifies decision-making for clinicians, and it allows them to offer therapy to the broadest possible patient population.” In the highest patient eosinophil count group, tozorakimab helped chart a 43% reduction in exacerbation risk, which Barr stressed were “unprecedented data.” In the mid-level group, AZ’s drug delivered a 23% reduction and, in the lowest group, a 34% reduction in eosinophils, which Barr said suggests efficacy “in all patient subgroups.” As for AZ’s recent guidance upgrade on the medicine’s sales opportunity, the lift from a $3 billion to $5 billion range to $5 billion plus was informed by multiple factors, Barr said, including the fact that “in 2024, there were multiple competitors, and there aren’t anymore.” Additionally, “we know that this is a massive unmet medical need, and this is a really incredible set of data that we think will be very convincing to the clinical community,” Barr said. Looking ahead to a potential evolution of the COPD treatment landscape, Barr noted that most patients start treatment in the community with an option like a triple therapy, and for them, having an option like AstraZeneca’s inhaler Breztri will remain a “really important part” of that journey. But of the patients uncontrolled on triple therapy, which Barr described as “about half of them today,” just a “small fraction” are currently eligible for biologic therapy, which she emphasized AstraZeneca is working to change. Understanding that COPD is not a “one-size-fits-all” disease, AstraZeneca is also looking at its antibody drug Tezspire for patients with T2-driven disease, and the company continues to think about new mechanisms for tackling COPD through both systemic and inhaled drugs, Barr said.
Jaelyn Hammersley Earns Global Prize at International Science Fair
OPRF junior Jaelyn Hammersley has earned a fourth-place award at the 2026 Regeneron International Science and Engineering Fair (ISEF), the world’s largest and most prestigious international high school science and engineering competition.
Gatton Academy Senior Takes Home Third Award at Regeneron International Science and Engineering Fair
Gatton Academy senior Jiwoo Kim (Model Laboratory School) earned Third Award and a cash prize at the renowned Regeneron International Science and Engineering Fair (ISEF) in the cellular and molecular biology category.
ASMSA students qualify for Regeneron International Science and Engineering Fair
Several students from the Arkansas School for Mathematics, Sciences, and the Arts earned honors at the Arkansas State Science and Engineering Fair, with 10 students qualifying for this year's Regeneron International Science and Engineering Fair, according to a news release.
'A landmark moment for the field': FDA approves first-ever gene therapy for inherited deafness
A gene therapy made by Regeneron is the first treatment of its kind approved for genetic hearing loss.
300 Exceptional Teen Scientists Recognized for Innovative STEM Research in Nation’s Oldest and Most Prestigious High School Competition
Society for Science today announced the top 300 scholars in the Regeneron Science Talent Search 2026....
Recent Stanton graduate wins Humane Science Award from National Anti-Vivisection Society
Alan Alwakeel, a recent graduate of Stanton College Preparatory School in Jacksonville, Florida, was one of just five recipients of the prestigious Humane Science Award at the 2026 Regeneron International Science and Engineering Fair (ISEF). The award is presented by the National Anti-Vivisection Society (NAVS), a nonprofit devoted to the advancement of science without harming animals and the only animal advocacy group invited to award a prize at the ISEF. Each recipient received a $3,000 prize
2 Westchester County Teens Among 40 Regeneron Science Talent Search 2026 Finalists
Each finalist is awarded at least $25,000, and they'll compete in March for awards ranging from $40,000 to $250,000.
Winning science fair project in Vietnam beset by misconduct allegations as major high school competition looms
Comparison provided by Van Tu Duong A science competition for middle and high school students in Vietnam is embroiled in controversy as its winners head to next week’s Regeneron International Scien…
Regeneron Science Talent Search: 33 Long Island students named semifinalists
The number of winners is an historic low for the Island but still higher than any other region in the United States.
Regeneron podcast turns science learnings into immersive experience
Regeneron is showing off its science in a whole new light with its “Science Illuminated” series, a unique vide | Regeneron's "Science Illuminated" podcast series transforms scientific topics into a calming, meditative-style video and audio experience.
King School student named a finalist in Regeneron science competition
Leon Wang's grandfather died due to the effects of Alzheimer's, so the King School senior set about finding a way to slow the progress of the disease for his winning project.
DCAT Awards Grants To Student Scientists at the 2026 Regeneron International Science & Engineering Fair - DCAT Value Chain Insights
The Drug, Chemical & Associated Technologies Association (DCAT) has awarded $30,000 in grants to student scientists of six projects who participated in the Regeneron International Science & Engineering Fair (Regeneron ISEF), the…
Dothan senior breaks 75-year barrier with international science fair qualification
Alexis Saffold earned her spot in the Regeneron International Science and Engineering Fair by turning an everyday problem into a potential breakthrough.
Meet Seth Nabat, the 18-year-old California student who built a two-network machine-learning system to track particle collisions; he won $40,000
Every year, nearly 1,900 of the nation’s most promising high school seniors submit original research to the Regeneron Science Talent Search (Regeneron STS), the oldest and most prestigious science and mathematics competition in the United States. According to the Society for Science, which runs the competition, the Regeneron STS recognises and empowers young scientists who are developing ideas that could solve society’s most urgent challenges.
Westchester students named Regeneron Science Talent Search finalists
Westchester students among 40 students nationwide recognized for their original science research, achievement and leadership.
UTC-hosted Regional Science and Engineering Fair highlights STEM talent
Dozens of students from across the Chattanooga region gathered on Monday, March 9, at the University of Tennessee at Chattanooga’s Challenger STEM Learning Center to present their research projects to a panel of judges. The Chattanooga Regional Science and Engineering Fair has existed for 74 years and attracts both middle and high school students to showcase their projects and compete for the chance to advance to the Regeneron International Science and Engineering Fair.
Three MNPS Students Recognized Among Nation's Top Young Scientists
All three students are high school seniors and scholars in the School for Science and Math at Vanderbilt, a collaboration between the school district and Vanderbilt University that puts students on the university’s campus one day a week to work with professors and graduate students.
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and patented drugs.
Caddo Magnet student recognized nationally for science research. 'exceptional promise' in STEM
A Caddo Parish Magnet High School senior, Maya Trutschl, received national recognition for her innovative research, becoming one of the Top 300 Regeneron Science Talent Search 2026 Scholars.
Hundreds of students compete in Regeneron Westchester Science and Engineering Fair
Participants get the opportunity to showcase their research and have their work judged by local experts in the field.
Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment
$250,000 top award goes to Connor Hill in America’s longest running and most distinguished science and math competition Top $250,000 Regeneron Science Talent Search Winner Named Regeneron and Society for Science announced that Connor Hill, 17, of State College, Pennsylvania, won the top award of $250,000 in the 2026 Regeneron Science Talent Search (STS), a program of Society for Science. TARRYTOWN, N.Y. and WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. and Societ
Bellevue teens targeting salmon die-offs and mental health win big at international science fair
Lakshmi Agrawal, a senior at Interlake High School, and Anusha Arora, a sophomore who also attends Interlake, were among more than 1,700 students from roughly 60 countries who competed at the Regeneron International Science and Engineering Fair in Phoenix.
Five MCPS Seniors Named Regeneron Science Talent Search Scholars
Five Montgomery County Public Schools seniors have been named among the 300 scholars selected nationwide for the 2026 Regeneron Science Talent Search, one of the country’s most prestigious science and […]
Spokane students qualify to attend prestigious science and engineering competition
SPOKANE, Wash. – Eight high school students from Spokane will travel to Arizona in May for the prestigious Regeneron International Science and Engineering Fair.
Greater San Diego Science and Engineering Fair Students Win Big at the 75th California Science and Engineering Fair
The 75th California Science and Engineering Fair (CSEF) took place April 11–12 at California Lutheran University in Thousand Oaks, bringing together 900 of the best of 1st place winners from regional competitions covering 58 counties across the state, including the Greater San Diego Science and Engineering Fair (GSDSEF). GSDSEF students earned 40 awards at the event, including two of only six highly coveted spots to the prestigious Regeneron International Science and Engineering Fair (ISEF). Sev
Meet Rachel Chen, the 18-year-old Los Angeles student who expanded a 1997 quantum-math idea to describe entire particle systems with simple diagrams; she won $100,000
At just 18, Rachel Chen has taken a decades-old mathematical idea and expanded it into a visual framework for understanding complex quantum systems, earning her a $100,000 award in the 2026 Regeneron Science Talent Search.
Greater San Diego Science and Engineering Fair Students Win 8 Awards at the 76th Regeneron International Science and Engineering Fair
/PRNewswire/ -- The 76th Regeneron International Science and Engineering Fair (ISEF), the world's largest precollege science and engineering competition,...
High schoolers are using AI to tackle cancer and build robotic surgeons
Finalists in the Society for Science and Regeneron $1.8 million science competition are increasingly turning to machine learning, and organizers are balancing innovation with misuse.
Two seniors win $4,000 for Farragut High School in math and science competition
Two Farragut High School Seniors were among 300 chosen in the 2026 Regeneron Science Talent Search math and science competition, winning a total of $4,000 for their school.
Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiative
President Donald Trump on Thursday announced a deal with drugmaker Regeneron to lower the cost of its pharmaceutical products as part of the White House’s signature drug pricing initiative.
Meet Mythreya Dharani, the 18-year-old New Jersey student who built an AI model to predict how individual tumors will respond to the chemotherapy drug cisplatin
Mythreya Dharani’s achievements in the high school science research arena are few and far between. The Society for Science, which organizes the prestigious Regeneron Science Talent Search, announced that 18-year-old Mythreya from New Jersey developed an AI model to predict how individual tumors would respond to the chemotherapy drug cisplatin.
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce Biotech has learned. The trial, which began only back in April, was a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score following treatment with SAR445399 compared with placebo in adults aged 18 to 80 years with NCFB, a chronic lung disease. The trial was officially reported as halted on July 29, the day before Sanofi’s second-quarter earnings call. The decision to pause the trial was made “as part of a company-wide portfolio review for strategic business reasons,” and not due to safety concerns, a Sanofi spokesperson told Fierce. The move to pause the NCFB trial comes during a trying time for Sanofi following a year filled with a series of trial fails. In February, the French pharma ousted CEO Paul Hudson and appointed Merck KGaA leader Belén Garijo, M.D., Ph.D., to steer the ship. Since then, Garijo has been doing a deep dive on correcting the company’s strewn R&D and clinical strategies. On July 24, Sanofi scrapped amlitelimab for atopic dermatitis, despite its lore as being a potential $5 billion blockbuster. During its second-quarter report, the company abandoned two more assets, balinatunfib and itepekimab, following failed trial results in psoriasis and chronic obstructive pulmonary disease, respectively. SAR445399, only first revealed by Sanofi in 2023, is an anti-interleukin-1 receptor 3 monoclonal antibody developed to block the interleukin 1, 33, and 36 cytokine pathways. These pathways can be important in chronic immune-related dermatologic diseases, such as atopic dermatitis and hidradenitis suppurativa, as well as respiratory conditions, such as NCFB. Related Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues NCFB affects roughly half a million people in the U.S., with a global incidence of greater than one million cases. In August 2025, Insmed received FDA approval for Brinsupri, a DPP1 inhibitor targeting neutrophil activation, for treatment of NCFB in adults and kids ages 12 and older. The British biotech Infex Therapeutics showed promising NCFB phase 2a data using their monoclonal antibody, INFEX702, which acts by disabling Pseudomonas aeruginosa, a bacteria known to be a major pathogen of NCFB. Sanofi is currently running a separate phase 2 study testing SAR445399 as a potential treatment for the inflammatory skin condition hidradenitis suppurativa.
Two GCPS Students named Regeneron Science Scholars
Two Gwinnett County Public Schools (GCPS) students have been named 2026 Regeneron Science Talent Search Scholars.
Why This Regeneron Rival Just Skyrocketed 90%
Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' Eylea.
Shreveport student honored as top 300 scholar in Science Talent Search
Maya Trutschl of Caddo Parish Magnet High School was awarded for her project, 'Automated Pressure Injury Risk Prediction and Prevention: Clinical Validation Study,' in the Regeneron Science Talent Search 2026, which recognizes 300 scholars from 826 high schools across 46 states, Washington, D.C., Northern Mariana Islands, Puerto Rico, and 16 countries.
Hands-on science can be cool
After spending many long days conducting experiments to find a new way to combat bacterial infections in crops, Misha Hegde and Mia Soleil Maurer have been rewarded with international recognition and access to top research facilities. But these are not typical scientists. They are 16-year-old German high school students.“Our supervisor told us that in order to start a project, you need to begin with either a question or a problem,” says Misha, adding that she and Mia had read about antibiotic resistance in certain plants being treated for bacterial infections. “We found out that antibiotics overuse is very common in agriculture,” explains Mia. “Our aim was to create an alternative to antibiotics and to try to raise awareness of the problem of overusing antibiotics.”Their subsequent research has focused on harnessing bacteriophages, the natural predators of bacteria, to eliminate pathogens threatening food crops treated with antibiotics. At the Schuldorf Bergstraße Jugend forscht MakerLab in Seeheim-Jugenheim, located in the German state of Hesse, they discovered a novel phage that infects the Rhizobium rhizogenes bacterium, which causes the hairy root disease that can reduce yields of tomatoes, carrots, soya beans and other food staples.The students believe their method could curb antibiotic use, while protecting plants from infections without disturbing the natural soil microbiome. “The application of phages is host-specific, so they would only kill the targeted pathogen or disease-causing bacteria,” explains Mia. It may also offer environmental benefits, since applying antibiotics can contaminate groundwater.Getting to this point has not been easy. The childhood friends admit to feeling frustrated when their trials did not yield the expected results. “We spent six months on our first experiment, just doing the same thing over and over and over again, to the point where we thought, is it even worth it? Why are we doing this?” Misha says. “You just need to be brave enough to take that first step and keep going.”The benefits of inquiry-based learningTheir determination has paid off. In 2025, the pair won first prize in biology at Jugend forscht, Germany’s national competition for young people interested in science, technology, engineering and mathematics. They were also among the winners of the German Research Foundation Europa-Preis, which is awarded to selected national winners at Jugend forscht, and took third place in the 2025 European Union Contest for Young Scientists.The Jugend forscht Foundation opens doors for young people to connect with scientists as well as industry professionals. Jessica Bönsch, executive director of the Foundation, sees Misha and Mia as prime examples of how young people can develop a deeper understanding of science through their own research projects. “The experience of working on your own research question is very important,” she explains, adding that “inquiry-based learning engages with real-life problems in a way that can be more motivating than traditional classroom teaching.”The Jugend forscht Foundation offers financial support through sponsor pools in Germany’s federal states. Some projects are developed in cooperation with student research centres, university labs or informal collaborative learning areas called makerspaces. Other activities start as hands-on “garage projects” and can grow within the Jugend forscht network and infrastructure.The Jugend forscht Foundation is also a partner of Science Comes to Town, an EU initiative to strengthen public awareness about science and create bridges between researchers and communities. The EU-financed project involves universities, research institutions and other stakeholders in three host cities — Brest (France), Kiel (Germany) and Split (Croatia).“It's so important for people not to live in a bubble, because I think science can be very scary if you misunderstand it,” Mia says of SCTT. The initiative’s aim of raising awareness about science is “absolutely amazing,” Misha adds. “I think it's the best way to kind of make science digestible for the public. In a world where misinformation in science is getting more radical, more dangerous, becoming more of a threat to the trust in scientific infrastructure and foundations, we need such programmes.”Misha and Mia also believe that SCTT can help break down gender stereotypes in science by encouraging young women to study and pursue careers in scientific fields. Both students have benefited from female mentors and encouragement they had when they were much younger. Mia’s love of science began with a class trip to a lab, while Misha — with a smile on her face — says she wanted to study history until “a teacher kind of coerced me into joining a school science club.”Recognition beyond EuropeIn May, Misha and Mia were among the finalists at the Regeneron International Science and Engineering Fair held in Phoenix, Arizona, and involving nearly 1,700 pre-university students from over 60 countries. “It was very crazy because there were so many people and so many teenagers interested in science,” Mia recalls. The event was also challenging. “It was eight hours of continuously presenting your project,” adds Misha.Attending the fair was a chance for the young women to see first-hand the value of international collaboration as well as how research cultures differ. “America is a bit more willing to take risks, and I think that's something we can learn about here in Europe,” Misha explains. However, she continues, “I think Europe has the talent, has the innovation and has the resources” to be competitive.Misha and Mia plan to continue their phage experiments in the new school year, inspired by the project’s hands-on nature and the support they receive from their supervisors. They have also attracted the interest of professional scientists and received invitations to leading research facilities, including the Centre for Synthetic Microbiology, jointly run by the University of Marburg and the Max Planck Institute for Terrestrial Microbiology in Germany. “It is so cool that we can do something to try to move the world in our school and at this age,” Mia says.After completing secondary school, Mia plans to study microbiology and pursue a career in medical research, focusing on Ebola and other infectious diseases. “This has been my dream for so long,” she says. Her friend Misha is interested in biological research with a focus on medicine. “I've gotten addicted to the process of going to the lab, planning out experiments, then failing, trying again,” Misha says. “I think there's just so much to be discovered, so much to be done.”The students' names and photos were published with the permission of their parents.Science|Business, which connects policymakers, academics and industry through its news reporting, analysis and events, is an SCTT partner.
UCF Grad’s Mission to Build Pipeline of Young Innovators
Guided by their two-time alum instructor and UCF researchers, three Oviedo High School students are ready to represent Central Florida at the Regeneron International Science and Engineering Fair (ISEF).
How an 18-year-old's love of origami helped him win $100,000
Hikaru Kuribayashi used origami-inspired technology to win a $100,000 prize at the 2026 Regeneron International Science and Engineering Fair in May.
Watch live: Trump gives remarks on health care affordability
President Trump is hosting an event at the White House on Thursday afternoon centered on health care affordability. Trump is expected to announce a new deal with pharmaceutical company Regeneron, a…
Gresham juniors Alexandra Harpole, Zoey Mattingly join international science fair
A pair of Gresham High juniors participated in an international science fair Alexandra Harpole and Zoey Mattingly joined the week-long Regeneron International Science and Engineering Fair, which was held May […]
Meet Jerry Xu, the 17-year-old Massachusetts student who built an AI program that turns protein structures into strings of numbers; he won $90,000
Imagine, what if a protein's complex 3-D structure could be converted into a simple string of numbers—and that string could help scientists understand what the protein does? That’s the premise of an innovative AI model developed by 17-year-old Jerry Xu of Lexington, Massachusetts, who earned $90,000 in the Regeneron Science Talent Search for his research, states an online report by the Society for Science.
Los Alamos High School Freshman Linus Plohr Earns 3rd Place Award At 2026 Regeneron International Science & Engineering Fair
Los Alamos High School freshman Linus Plohr placed 3rd in the Behavioral and Social Science category at the 2026 Regeneron International Science and Engineering Fair. Courtesy photo Brothers Tate a…
33 LI students named Regeneron Science Talent Search semifinalists
High School Students Advance from State Science and Engineering Fair to International Competition
Charleston, W.Va. - The West Virginia Department of Education (WVDE) is pleased to announce that Pavan Subramani from Morgantown High School (Monongalia County), Iqraa Zaman from George Washington High School (Kanawha County) and the team of Jaxon Milam and Joseph Nodurft from the Linsly School (Ohio County) have advanced from the 72nd annual West Virginia State Science and Engineering Fair (WVSSEF) to the Regeneron International Science and Engineering Fair (ISEF). The state-level fair serves as the qualifier for the ISEF, and these four students will represent the Mountain State in Phoenix in May.To compete in the WVSSEF, students in Grades 3-12 had to win their local, county and regional science and engineering fairs. Today’s competition resulted in 48 first place winners, 53 second place winners and 46 third place winners. For the full detailed list, view the 2026 WVSSEF Official Results.The WVSSEF challenges students to think critically about the world around them, encouraging them to find answers to unsolved questions and address problems by introducing proactive solutions. Students are also provided the opportunity to present their projects to judges—industry professionals and university professors—to discuss the research findings, scientific methodologies and hypotheses involved in their work.“The West Virginia Science and Engineering Fair is a highlight of every school year, as it brings some of the Mountain State's most accomplished students together as a showcase of the immense talent and potential they possess," said State Superintendent of Schools Michele L. Blatt. "These young scholars show time and time again that the future economy of West Virginia is bright. The attention to detail in every project and the passion and joy expressed by our students are truly inspiring."The WVSSEF featured 273 aspiring scientists, chemists and engineers who presented 209 projects featuring material science, animal science, plant science, physics, astronomy, engineering and more.View event photos.
Long Island student takes top spot at state science fair
11 local teens have advanced from the state level to the Regeneron International Science and Engineering Fair in Phoenix on May 9-15.
With $100 worth of supplies, this Chula Vista teen just won a prestigious international science award
Ihan Sung, 17, won fourth place in the Regeneron International Science and Engineering Fair. Two other students from Eastlake High also competed.
Shreveport student honored as top 300 scholar in Science Talent Search
Maya Trutschl of Caddo Parish Magnet High School was awarded for her project, ‘Automated Pressure Injury Risk Prediction and Prevention: Clinical Validation Study,’ in the Regeneron Sci…
Dunbar Students Win International Science Awards
The Regeneron ISEF drew over 1,700 competitors from some 60 countries.